semaglutide deaths 2024 flow trial renal outcomes Results from this major show that reduced the risk of Study finds semaglutide reduces CKD

Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)

Hypoglycaemia (low blood glucose) represents the most clinically significant cause of light-headedness in Ozempic users

Tied events were handled using the Exact method 54,55 , if possible, or Efrons method 56 , if not

$249 billion in healthcare expenditures, productivity losses, crime, motor vehicle accidents and fire losses